カテゴリ： GlobalData, フランス, 企業調査

French National Institute of Health and Medical Research：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：French National Institute of Health and Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12320
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：88
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immunology, inflammation, genetics, cancer, infectiology and microbiology, physiopathology, public health, health technologies, metabolism, cell biology and immunology, among others. It provides services in the areas of human diseases and research findings to the medical community, and to both national and international partners. INSERM also conducts translational research and development services. It operates research units and research centers. INSERM is headquartered in Paris, France.

French National Institute of Health and Medical Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deal Details 18
Venture Financing 18
Therachon Raises USD60 Million in Mezzanine Financing 18
ILiAD Biotech Raises USD0.6 Million in Venture Financing 20
Step Pharma Raises Additional USD10.1 Million in Series A Financing 21
ILiAD Biotech Raises USD4.7 Million in Financing 23
ILiAD Biotech Raises USD1.2 Million in Venture Financing 24
Therachon Raises Additional USD5 Million in Series A Financing Round 25
ILiAD Biotech Raises USD0.5 Million in Venture Financing 27
ILiAD Biotech Raises USD1 Million in Venture Financing 28
Inception IBD Raises USD14.1 Million in Series A Financing 29
ILiAD Biotech Raises USD0.6 Million in Venture Financing 30
Therachon Raises USD35 Million in Series A Financing 31
Eyevensys Secures Venture Funding 32
Sensorion Raises USD4.6 Million in Venture Financing 33
AAVLife Raises US$12 Million In Series A Financing 34
Aelis Farma Raises USD1.7 Million in Venture Financing 35
Inotrem Raises US$25 Million In Series A Financing 36
Hemarina Raises US$8 Million In Series B Financing 38
Eyevensys Raises US$2 Million In First Round Of Financing 39
Partnerships 40
Telix Pharma Enters into Research Agreement with INSERM and ARRONAX 40
Genisphere Enters into Agreement with Inserm 41
TxCell Enters into R&D Agreement with Inserm Transfert 42
Evotec Enters into Research Agreement with Inserm Transfert 43
Pierre Fabre Medicament Partners with Inserm Transfert 44
AstraZeneca Enters into Research Agreement with Inserm 45
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 46
Mifcare Enters into Agreement with Inserm 47
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 48
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 50
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 52
Licensing Agreements 54
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 54
Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 55
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 56
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 57
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 58
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 59
Brainvectis Enters into Licensing Agreement with INSERM 60
ProGeLife Enters into Licensing Agreement with University of Bordeaux and INSERM Transfert 61
Inserm Transfert Enters into Licensing Agreement with HalioDx 62
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 63
IntegraGen Enters into Licensing Agreement with Inserm 65
AAVLife Amends Licensing Agreement with Inserm Transfert 66
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 67
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 68
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 69
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 70
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 71
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 72
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 74
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 76
Equity Offering 77
Horama Spin off from Inserm Transfert 77
French National Institute of Health and Medical Research – Key Competitors 78
French National Institute of Health and Medical Research – Key Employees 79
French National Institute of Health and Medical Research – Locations And Subsidiaries 80
Head Office 80
Other Locations & Subsidiaries 80
Affiliate 80
Recent Developments 81
Government and Public Interest 81
Sep 03, 2018: Gene-hunters make sense of a new immune disease 81
Aug 31, 2018: Novel brain network linked to chronic pain in Parkinson’s disease 83
May 02, 2018: Discovery of a first genetic cause of Whipple’s disease 84
Apr 26, 2018: Discovery of a future therapy for hemoglobinopathies 85
Dec 20, 2017: NORD Awards Five New Grants for Rare Disease Research 86
Other Significant Developments 87
Aug 20, 2018: Bioengineered tooth replacement opens doors to new therapies 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88

List of Tables
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Key Facts 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
French National Institute of Health and Medical Research, Deals By Therapy Area, 2012 to YTD 2018 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Therachon Raises USD60 Million in Mezzanine Financing 18
ILiAD Biotech Raises USD0.6 Million in Venture Financing 20
Step Pharma Raises Additional USD10.1 Million in Series A Financing 21
ILiAD Biotech Raises USD4.7 Million in Financing 23
ILiAD Biotech Raises USD1.2 Million in Venture Financing 24
Therachon Raises Additional USD5 Million in Series A Financing Round 25
ILiAD Biotech Raises USD0.5 Million in Venture Financing 27
ILiAD Biotech Raises USD1 Million in Venture Financing 28
Inception IBD Raises USD14.1 Million in Series A Financing 29
ILiAD Biotech Raises USD0.6 Million in Venture Financing 30
Therachon Raises USD35 Million in Series A Financing 31
Eyevensys Secures Venture Funding 32
Sensorion Raises USD4.6 Million in Venture Financing 33
AAVLife Raises US$12 Million In Series A Financing 34
Aelis Farma Raises USD1.7 Million in Venture Financing 35
Inotrem Raises US$25 Million In Series A Financing 36
Hemarina Raises US$8 Million In Series B Financing 38
Eyevensys Raises US$2 Million In First Round Of Financing 39
Telix Pharma Enters into Research Agreement with INSERM and ARRONAX 40
Genisphere Enters into Agreement with Inserm 41
TxCell Enters into R&D Agreement with Inserm Transfert 42
Evotec Enters into Research Agreement with Inserm Transfert 43
Pierre Fabre Medicament Partners with Inserm Transfert 44
AstraZeneca Enters into Research Agreement with Inserm 45
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 46
Mifcare Enters into Agreement with Inserm 47
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 48
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 50
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 52
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 54
Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 55
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 56
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 57
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 58
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 59
Brainvectis Enters into Licensing Agreement with INSERM 60
ProGeLife Enters into Licensing Agreement with University of Bordeaux and INSERM Transfert 61
Inserm Transfert Enters into Licensing Agreement with HalioDx 62
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 63
IntegraGen Enters into Licensing Agreement with Inserm 65
AAVLife Amends Licensing Agreement with Inserm Transfert 66
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 67
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 68
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 69
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 70
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 71
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 72
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 74
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 76
Horama Spin off from Inserm Transfert 77
French National Institute of Health and Medical Research, Key Competitors 78
French National Institute of Health and Medical Research, Key Employees 79
French National Institute of Health and Medical Research, Subsidiaries 80
French National Institute of Health and Medical Research, Affiliate 80

List of Figures
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[French National Institute of Health and Medical Research：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Ramco-Gershenson Properties Trust：企業のM&A・事業提携・投資動向
    Ramco-Gershenson Properties Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ramco-Gershenson Properties Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Hess Corporation：企業の戦略・SWOT・財務情報
    Hess Corporation - Strategy, SWOT and Corporate Finance Report Summary Hess Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Florida Keys Electric Cooperative Association, Inc.：発電所・企業SWOT分析
    Florida Keys Electric Cooperative Association, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analys …
  • Coca-Cola FEMSA SAB de CV：戦略・SWOT・企業財務分析
    Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Colorado State University-製薬・医療分野：企業M&A・提携分析
    Summary Colorado State University (CSU) is a public research university that offers various academic programs. It provides graduate degree programs, undergraduate degree programs, research programs, summer programs and honor programs. Its schools and programs include graduate school, international p …
  • Siemens Heat Transfer Technology BV：企業の戦略的SWOT分析
    Siemens Heat Transfer Technology BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Reinsurance Group of America Inc：企業の戦略・SWOT・財務分析
    Reinsurance Group of America Inc - Strategy, SWOT and Corporate Finance Report Summary Reinsurance Group of America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Gas Natural Fenosa：企業のM&A・事業提携・投資動向
    Gas Natural Fenosa - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gas Natural Fenosa Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Fortis Inc (FTS)：電力：M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • The McClatchy Company (MNI)：企業の財務・戦略的SWOT分析
    The McClatchy Company (MNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kurabo Industries Ltd (3106)：企業の財務・戦略的SWOT分析
    Kurabo Industries Ltd (3106) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • MRC Global Inc (MRC)：石油・ガス：M&Aディール及び事業提携情報
    Summary MRC Global Inc (MRC) is a provider of pipe, valves and fittings. Its product portfolio include carbon steel pipe, carbon steel fittings and flanges, valve automation, stainless and alloy pipe, stainless and alloy fittings and flanges, specialty products, industrial products, oilfield product …
  • Drax Group Plc：発電所・企業SWOT分析
    Drax Group Plc – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Drake & Scull International (DSI)：企業の財務・戦略的SWOT分析
    Drake & Scull International (DSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ampio Pharmaceuticals Inc (AMPE)：企業の財務・戦略的SWOT分析
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Hyatt Hotels Corporation：企業の戦略・SWOT・財務情報
    Hyatt Hotels Corporation - Strategy, SWOT and Corporate Finance Report Summary Hyatt Hotels Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Iroko Pharmaceuticals LLC-製薬・医療分野：企業M&A・提携分析
    Summary Iroko Pharmaceuticals LLC (Iroko) is a specialty pharmaceutical company that develops and commercializes pharmaceutical products. The company’s products comprise low dose Nonsteroidal anti-inflammatory drugs such as meloxicam, indomethacin, and diclofenac that are in various stages of noncli …
  • Mologic Ltd-医療機器分野：企業M&A・提携分析
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company’s products include bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit. Its experti …
  • OWC Pharmaceutical Research Corp (OWCP)：製薬・医療：M&Aディール及び事業提携情報
    Summary OWC Pharmaceutical Research Corp (OWC Pharmaceutical), formerly Dynamic Applications Corp, is a drug development company that discovers, develops, and commercializes cannabis-based novel therapeutics products and treatments for several medical conditions. The company offers sublingual solubl …
  • Cypress Semiconductor Corporation (CY)：企業の財務・戦略的SWOT分析
    Cypress Semiconductor Corporation (CY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆